Net Worth Advisory Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$570K Sell
7,283
-190
-3% -$13K 0.14% 165
2026
Q1
$483K Buy
7,473
+656
+10% +$46.2K 0.1% 207
2025
Q4
$459K Buy
6,817
+1,062
+18% +$71.4K 0.09% 223
2025
Q3
$422K Sell
5,755
-297
-5% -$19.7K 0.12% 190
2025
Q2
$315K Buy
6,052
+426
+8% +$24.2K 0.07% 288
2025
Q1
$359K Sell
5,626
-52
-0.9% -$3.02K 0.11% 208
2024
Q4
$271K Sell
5,678
-42
-0.7% -$2.15K 0.08% 278
2024
Q3
$327K Buy
+5,720
New +$328K 0.1% 245

Other funds holding HALO

Net Worth Advisory Group's HALO Position: Q2 2026 in Review

Net Worth Advisory Group reduced its Halozyme (HALO) stake by 2.5% in Q2 2026, selling an estimated $13K and leaving 7,283 shares worth $570K. The position accounts for 0.14% of the portfolio, ranked #165.

Net Worth Advisory Group first reported a position in HALO in Q3 2024 and has held it in 8 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Net Worth Advisory Group held 7,283 shares of Halozyme worth $570K as of Q2 2026.
  • Net Worth Advisory Group sold 190 Halozyme shares in Q2 2026, an estimated $13K.
  • Halozyme made up 0.14% of Net Worth Advisory Group's portfolio in Q2 2026, its #165 holding.
  • Net Worth Advisory Group first reported a position in Halozyme in Q3 2024 and has held it in 8 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Net Worth Advisory Group's 13F filing for Q2 2026, filed 14 Jul 2026.